Useful Links

Learn more about von Willebrand disease (VWD) and get support by accessing these Web sites.

AllAboutBleeding
This is the only Web site dedicated exclusively to increasing awareness about VWD, with an extensive resource section.
allaboutbleeding-us.com

Centers for Disease Control and Prevention (CDC)
CDC's Division of Blood Disorders works to prevent and reduce complications experienced by persons with blood disorders; this link takes you right to a discussion on hemophilia and VWD.
http://www.cdc.gov/ncbddd/hbd/hemophilia.htm

CSL Behring
CSL Behring specializes in plasma therapies to improve the quality of life in patients with bleeding disorders, immune deficiencies, inherited emphysema, and other conditions.
http://www.cslbehring-us.com/

Humate-P^®
If Stimate^® Nasal Spray isn’t right for your VWD, learn about an important treatment option, Humate-P^®.
Humatep.com

LA Kelley Communications
Find educational tools, presentations, and workshops about bleeding disorders at this site.
www.kelleycom.com

LadyBugs
This organization provides support for women with bleeding disorders, especially those who may have been undiagnosed and/or improperly treated.
http://www.ladybugssupport.com/

Mayo Clinic
This renowned healthcare system has a comprehensive disease Web site with information on VWD.
http://www.mayoclinic.com/health/von-willebrand-disease/DS00903

National Heart, Lung, and Blood Institute (NHLBI)
Find more information about VWD, including diagnosing, treating, and living with VWD.
http://www.nhlbi.nih.gov/health/dci/Diseases/vWD/vWD_WhatIs.html

National Hemophilia Foundation
NHF, which is devoted to the bleeding disorders community, provides information on VWD, upcoming conferences, and more.
http://www.hemophilia.org

World Federation of Hemophilia
This organization improves and sustains care for people with inherited bleeding disorders.
http://www.wfh.org

Important Safety Information

Stimate Nasal Spray is indicated for patients with hemophilia A with Factor VIII coagulant activity levels greater than 5%. Desmopressin acetate is not indicated for the treatment of hemophilia A with Factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have Factor VIII antibodies.

Stimate^® Nasal Spray is indicated for patients with mild to moderate classic type 1 von Willebrand disease (VWD) with Factor VIII levels greater than 5%. Stimate^® Nasal Spray is not indicated for the treatment of severe classic VWD (Type I) and when there is evidence of an abnormal molecular form of Factor VIII antigen.

Stimate^® Nasal Spray is contraindicated if you have a known hypersensitivity to desmopressin or any of the components of Stimate. Stimate should not be used by patients with type 2B VWD, since platelet aggregation may be induced. Stimate Nasal Spray is for intranasal use only.

To reduce the potential for water intoxication or hyponatremia, especially in the young and the elderly, patients using desmopressin may be advised to reduce fluid intake, ingesting only enough to satisfy thirst. Your doctor will monitor for a rare occurrence of an extreme decrease in plasma osmolality that could result in seizures, possibly leading to coma.

Other adverse reactions reported with use of injectable and/or intranasal desmopressin acetate include headache, nausea, somnolence (sleepiness), dizziness, chest pain, palpitations and tachycardia (rapid heartbeat), and severe allergic reactions, including anaphylaxis. See full prescribing information for a complete list of adverse reactions.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Important Safety Information for Humate-P

Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.

Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.

Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.